GlassScriptPhysician profile
Abinash C Roy
NPI 1295825818
$621.05
in general payments reported to CMS, 2019-2025
11 companies · $77.51 in 2025
The $77.51 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.42 · 2021: $47.92 · 2022: $274 · 2023: $177 · 2025: $77.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $1.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.61 |
| Education | $1.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.25 | 2021-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $117.14 | 2021-2023 | |
| Vantive US Healthcare LLC | $76.41 | 2025 | Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $70.80 | 2022-2023 | Lokelma |
| Travere Therapeutics, INC. | $58.98 | 2022-2025 | Thiola |
| Alexion Pharmaceuticals, INC. | $44.43 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $32.47 | 2022-2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $32.12 | 2019 | |
| Calliditas Therapeutics US INC. | $31.38 | 2022-2023 | Tarpeyo |
| Vifor Pharma, INC. | $18.69 | 2023 | Korsuva, Veltassa |
| Mallinckrodt Hospital Products INC. | $17.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abinash Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.